Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis

Thrombosis and Haemostasis

Volumn 102, Issue 2, 2009, Pages 248-257

  Jennings, Lisa K ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antiplatelet therapy; Haemostasis; Inflammation; Platelet activation; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; AR C69931; CANGRELOR; CD40 LIGAND; CLOPIDOGREL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN RECEPTOR ANTAGONIST; FR 171113; GELATINASE A; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; RANTES; REACTIVE OXYGEN METABOLITE; RWJ 58259; SCH 530348; THROMBIN; THROMBOCYTE FACTOR 4; THROMBOCYTE RECEPTOR; THROMBOXANE A2; TICAGRELOR; TICLOPIDINE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD CLOTTING; BLOOD VESSEL INJURY; BRAIN HEMORRHAGE; DRUG FATALITY; ENDOTHELIUM CELL; HEART INFARCTION; HEMOSTASIS; HUMAN; INFLAMMATION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOGENESIS; THROMBOSIS; ANIMAL; BIOLOGICAL MODEL; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; LEUKOCYTE; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE;

ANIMALS; ATHEROSCLEROSIS; BLOOD COAGULATION; BLOOD PLATELETS; HEMOSTASIS; HUMANS; INFLAMMATION; LEUKOCYTES; MODELS, BIOLOGICAL; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RECEPTOR, PAR-1; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 70350459370     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-03-0192     Document Type: Article

References (91)

1. Brass LF. Thrombin and platelet activation. Chest 2003; 124: 18S-25S.
2. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
3. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 2008; 28: 403-412.
4. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006; 99: 1293-1304. (Pubitemid 44949665)
5. Mann KG. Thrombin formation. Chest 2003; 124: 4S-10S.
6. Brummel KE, Paradis SG, Butenas S, et al. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-152. (Pubitemid 35177440)
7. Vu TK, Hung DT, Wheaton VI, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-1068.
8. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-1814. (Pubitemid 41716567)
9. Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 2006; 114: 1070-1077.
10. Landis RC. Protease activated receptors: clinical relevance to hemostasis and inflammation. Hematol Oncol Clin North Am 2007; 21: 103-113.
11. Martorell L, Martinez-Gonzalez J, Rodriguez C, et al. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost 2008; 99: 305-315. (Pubitemid 351230960)
12. De Candia E, Hall SW, Rutella S, et al. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem 2001; 276: 4692-4698. (Pubitemid 37371351)
13. Brass LF, Zhu L, Stalker TJ. Novel therapeutic targets at the platelet vascular interface. Arterioscler Thromb Vasc Biol 2008; 28: s43-50.
14. Wegener KL, Partridge AW, Han J, et al. Structural basis of integrin activation by talin. Cell 2007; 128: 171-182. (Pubitemid 46048890)
15. Mondoro TH, White MM, Jennings LK. Active GPIIb-IIIa conformations that link ligand interaction with cytoskeletal reorganization. Blood 2000; 96: 2487-2495.
16. Moser M, Nieswandt B, Ussar S, et al. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 2008; 14: 325-330. (Pubitemid 351347914)
17. Patil S, Newman DK, Newman PJ. Platelet endothelial cell adhesion molecule-1 serves as an inhibitory receptor that modulates platelet responses to collagen. Blood 2001; 97: 1727-1732. (Pubitemid 32217240)
18. Nanda N, Andre P, Bao M, et al. Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling. Blood 2005; 106: 3028-3034. (Pubitemid 41565895)
19. Israels SJ, McMillan-Ward EM. CD63 modulates spreading and tyrosine phosphorylation of platelets on immobilized fibrinogen. Thromb Haemost 2005; 93: 311-318.
20. Goschnick MW, Lau LM, Wee JL, et al. Impaired "outside-in" integrin alphaIIbbeta3 signaling and thrombus stability in TSSC6-deficient mice. Blood 2006; 108: 1911-1918.
21. Prevost N, Woulfe DS, Jiang H, et al. Eph kinases and ephrins support thrombus growth and stability by regulating integrin outside-in signaling in platelets. Proc Natl Acad Sci U S A 2005; 102: 9820-9825. (Pubitemid 40993651)
22. Bouchard BA, Tracy PB. Platelets, leukocytes, and coagulation. Curr Opin Hematol 2001; 8: 263-269.
23. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 2002; 88: 186-193.
24. Siljander P, Farndale RW, Feijge MA, et al. Platelet adhesion enhances the glycoprotein VI-dependent procoagulant response: Involvement of p38 MAP kinase and calpain. Arterioscler Thromb Vasc Biol 2001; 21: 618-627. (Pubitemid 32323397)
25. Storey RF, Sanderson HM, White AE, et al. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925-934.
26. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
27. May AE, Seizer P, Gawaz M. Platelets: inflammatory firebugs of vascular walls. Arterioscler Thromb Vasc Biol 2008; 28: s5-10.
28. Langer HF, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2008; 99: 480-486. (Pubitemid 351549284)
29. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40. (Pubitemid 46066771)
30. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol 2004; 25: 489-495.
31. Subramaniam M, Frenette PS, Saffaripour S, et al. Defects in hemostasis in P-selectin-deficient mice. Blood 1996; 87: 1238-1242.
32. Massberg S, Enders G, Leiderer R, et al. Plateletendothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood 1998; 92: 507-515. (Pubitemid 28323713)
33. Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha. J Exp Med 1998; 187: 329-339. (Pubitemid 28080062)
34. Gawaz M, Neumann FJ, Dickfeld T, et al. Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation 1997; 96: 1809-1818.
35. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001; 104: 163-167.
36. Shiraki R, Inoue N, Kawasaki S, et al. Expression of Toll-like receptors on human platelets. Thromb Res 2004; 113: 379-385. (Pubitemid 38844368)
37. Zernecke A, Liehn EA, Fraemohs L, et al. Importance of junctional adhesion molecule-A for neointimal lesion formation and infiltration in atherosclerosisprone mice. Arterioscler Thromb Vasc Biol 2006; 26: e10-13. (Pubitemid 43732185)
38. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594. (Pubitemid 28157601)
39. Slupsky JR, Kalbas M, Willuweit A, et al. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 1998; 80: 1008-1014. (Pubitemid 28556707)
40. Santos-Martinez MJ, Medina C, Jurasz P, et al. Role of metalloproteinases in platelet function. Thromb Res 2008; 121: 535-542.
41. Lambert MP, Sachais BS, Kowalska MA. Chemokines and thrombogenicity. Thromb Haemost 2007; 97: 722-729.
42. von Hundelshausen P, Weber KS, Huo Y, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772-1777. (Pubitemid 32291415)
43. von Hundelshausen P, Koenen RR, Sack M, et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005; 105: 924-930. (Pubitemid 40170856)
44. Koenen RR, von Hundelshausen P, Nesmelova IV, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009; 15: 97-103.
45. Gawaz M, Brand K, Dickfeld T, et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin- 1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 2000; 148: 75-85.
46. Krotz F, Sohn HY, Gloe T, et al. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 2002; 100: 917-924. (Pubitemid 34832618)
47. da Costa Martins PA, van Gils JM, Mol A, et al. Platelet binding to monocytes increases the adhesive properties of monocytes by up-regulating the expression and functionality of beta1 and beta2 integrins. J Leukoc Biol 2006; 79: 499-507. (Pubitemid 44831227)
48. Schober A, Manka D, von Hundelshausen P, et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106: 1523-1529. (Pubitemid 35050881)
49. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil- interactions: linking hemostasis and inflammation. Blood Rev 2007; 21: 99-111.
50. Weyrich AS, Schwertz H, Kraiss LW, et al. Protein synthesis by platelets: historical and new perspectives. J Thromb Haemost 2009; 7: 241-246.
51. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154: 485-490. (Pubitemid 34286155)
52. Evangelista V, Manarini S, Di Santo A, et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 2006; 98: 593-595. (Pubitemid 43755277)
53. Weyrich AS, Denis MM, Schwertz H, et al. mTORdependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. Blood 2007; 109: 1975-1983. (Pubitemid 46348195)
54. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186.
55. Leytin V, Allen DJ, Lyubimov E, et al. Higher thrombin concentrations are required to induce platelet apoptosis than to induce platelet activation. Br J Haematol 2007; 136: 762-764. (Pubitemid 46246312)
56. Leytin V, Allen DJ, Mykhaylov S, et al. Thrombintriggered platelet apoptosis. J Thromb Haemost 2006; 4: 2656-2663.
57. Schulman SP. Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes. J Am Med Assoc 2004; 292: 1875-1882.
58. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294.
59. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
60. Lewis HD, Jr., Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403.
61. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714-1719. (Pubitemid 18156672)
62. Popma JJ, Ohman EM, Weitz J, et al. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 2001; 119: 321S-336S. (Pubitemid 32154208)
63. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Br Med J 1994; 308: 81-106. (Pubitemid 24052591)
64. Cattaneo M. P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents. Eur Heart J 2006; 27: 1010-1012.
65. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-1339.
66. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502. (Pubitemid 32758501)
67. Steinhubl SR, Berger PB, Mann JT, III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002; 288: 2411-2420.
68. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189. (Pubitemid 40397259)
69. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621. (Pubitemid 41552416)
70. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
71. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982-1988.
72. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
73. Rao SV, Eikelboom JA, Granger CB, et al. Bleeding and blood transfusion issues in patients with non-STsegment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1193-1204.
74. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. J Am Med Assoc 2004; 292: 1555-1562. (Pubitemid 39314961)
75. Rao SV, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96: 1200-1206. (Pubitemid 41505393)
76. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-1516. (Pubitemid 46517957)
77. De Miguel A, Ibanez B, Badimon JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008; 100: 196-203.
78. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-198. (Pubitemid 34113814)
79. Derian CK, Damiano BP, Addo MF, et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 2003; 304: 855-861.
80. Kato Y, Kita Y, Hirasawa-Taniyama Y, et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol 2003; 473: 163-169. (Pubitemid 36929880)
81. Vandendries ER, Hamilton JR, Coughlin SR, et al. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci USA 2007; 104: 288-292.
82. Maurice P, Legrand C, Fauvel-Lafeve F. Platelet adhesion and signaling induced by the octapeptide primary binding sequence (KOGEOGPK) from type III collagen. Faseb J 2004; 18: 1339-1347. (Pubitemid 39150349)
83. Suh TT, Holmback K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995; 9: 2020-2033.
84. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008; 51: 3061-3064. (Pubitemid 351821864)
85. Chintala M, Vemulapalli S, Kurowski S, et al. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in Cynomolgus monkeys. Atheroscler Thromb Vasc Biol 2008; 28: e32-e149. Abstract P579.
86. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373: 919-928.
87. Jennings LK, Earhart A, Becker RC, et al. H. Thrombin receptor antagonist (TRA;SCH530348) is a selective, potent inhibitor of PAR1 activity with predictable pharmacokinetics. Presented at American Heart Association Scientific Sessions November 4-7; 2007; Orlando, FL.; 2007.
88. Goto S YT, Ikeda Y, Yamaguchi H, et al. Phase II trial of the novel antiplatelet agent, SCH 530348, in Japanese patients with non-ST segment elevation acute coronary syndromes (NSTE ACS). Eur Heart J 2008; 29 (Suppl): 829. Abstract P4767.
89. Shinohara Y, Shimizu K., Jensen P . A phase II safety study of novel antiplatelet agent, SCH 530348, in Japanese patients with prior ischemic stroke. Int J Stroke 2008; 3 (Suppl 1): 139. Abstract PO01-193.
90. Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (Study P04737). 2008.
91. Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Acute Coronary Syndrome (TRACER) (Study P04736AM1). 2008.